Artemis Therapeutics Inc.
Artemis Therapeutics Inc. (ATMS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
atms · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Artemis Therapeutics Inc. (ATMS) measures how much investors pay for each dollar of the company's trailing earnings. ATMS's current PE ratio of N/A is calculated by dividing its stock price of $0.50 by its TTM earnings per share of -$0.00.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2003 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%32.3x
MedianQ3 · 75%107.3x
Max
At N/A, ATMS's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Shell Companies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Artemis Therapeutics Inc.You ATMS | $56M | N/A | — | -$0.00 |
 Alpha One Inc. AOAO | $49M | N/A | — | -$2.87 |
 Focus Impact BH3 Acquisition Co BHAC | $60M | N/A | — | -$2.85 |
 Clover Leaf Capital Corp. CLOE | $62M | N/A | — | -$0.18 |
 Iris Acquisition Corp IRAA | $45M | N/A | — | -$0.40 |
 James Maritime Holdings, Inc. JMTM | $48M | N/A | — | $0.00 |
 Kingswood Acquisition Corp. KWAC | $46M | 58.10x | — | $0.17 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-0.00 | — | |
2021-12-31 FY2021 | — | $-0.01 | — | |
2020-12-31 FY2020 | — | $-0.02 | — | |
2019-12-31 FY2019 | — | $-0.02 | — | |
2018-12-31 FY2018 | 3.26x | $0.10 | — | |
2017-12-31 FY2017 | — | $-0.23 | — | |
2016-12-31 FY2016 | — | $-0.05 | — | |
2015-12-31 FY2015 | — | $-0.16 | — | |
2014-12-31 FY2014 | 107.34x | $0.42 | — | |
2013-12-31 FY2013 | — | $-0.35 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Artemis Therapeutics Inc. (ATMS) measures how much investors pay for each dollar of the company's trailing earnings. ATMS's current PE ratio of N/A is calculated by dividing its stock price of $0.50 by its TTM earnings per share of -$0.00.
Frequently asked questions
ATMS pe ratio · 6 questionsATMS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.50 and TTM EPS of -$0.00. Data sourced from Financial Modeling Prep via ATMS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Artemis Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09